These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8389785)

  • 1. Other approaches to the treatment of chronic viral hepatitis.
    Carreño V; Marriott E; Quiroga JA
    J Hepatol; 1993; 17 Suppl 3():S127-9. PubMed ID: 8389785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome detection in liver and peripheral blood mononuclear cells: predictor factors of sustained response in patients with chronic hepatitis C.
    Berenguer M; Olaso V; Córdoba J; Gobernado M; Carrasco D; Berenguer J
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):899-903. PubMed ID: 8574725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection.
    Davis GL; Lau JY
    J Hepatol; 1995; 22(1 Suppl):110-4. PubMed ID: 7602061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment of chronic hepatitis C with interferon.
    Toyoda H; Nakano S; Takeda I; Kumada T; Sugiyama K; Osada T; Kiriyama S; Suga T; Ohki H; Ito O
    Am J Gastroenterol; 1994 Sep; 89(9):1453-7. PubMed ID: 7521572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study for relapse cases of chronic hepatitis C treated with interferon (IFN) and approach to more successful re-treatment of IFN].
    Iwabuchi S; Yoshida H; Fukui S
    Nihon Rinsho; 1994 Jul; 52(7):1810-6. PubMed ID: 7521423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
    Schalm SW; Hansen BE; Chemello L; Bellobuono A; Brouwer JT; Weiland O; Cavalletto L; Schvarcz R; Ideo G; Alberti A
    J Hepatol; 1997 May; 26(5):961-6. PubMed ID: 9186825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two years versus six months of interferon therapy for chronic hepatitis C.
    Farrell GC
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):93S-98S. PubMed ID: 9011483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.
    Shindo M; Arai K; Sokawa Y; Okuno T
    Ann Intern Med; 1995 Apr; 122(8):586-91. PubMed ID: 7887552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.